Figure 2.

Treatment Strategy for Advanced HCC and ICC.

The schematic illustration represents FDA-approved drugs for treatment of advanced HCC and ICC. First-line drugs for HCC include sorafenib, lenvatinib, atezolizumab plus bevacizumab, tremelimumab plus durvalumab and donafenib, whereas, for ICC, the combination of gemcitabine and cisplatin is currently proposed as first line. The bottom row represents corresponding second-line therapies that come in when patients are not suitable for their first-line therapy.